timothy sykes logo
RDHL Stock Shows Volatile Moves As Traders Watch Key Levels Thumbnail
G Google News

RDHL Stock Shows Volatile Moves As Traders Watch Key Levels

BRYCE TUOHEY•UPDATED AUG. 31, 2026, 7:48 AM ET
Reviewed by Tim Sykesand Fact-checked by Matt Monaco

Redhill Biopharma Ltd. shares surge as positive drug development news drives bullish sentiment, and stocks have been trading up by 139.03 percent.

Key Takeaways

  • RDHL has climbed from sub-$0.59 closes to about $0.66 over recent sessions, signaling short-term upside momentum on the daily chart.
  • Intraday, RDHL spiked above $2 before slamming down to the $1.50s, highlighting extreme volatility that active traders track closely.
  • The latest data show Redhill Biopharma Ltd. running a lean operation with only 35 employees, but a heavy accumulated deficit on the balance sheet.
  • RDHL’s negative returns on assets and high leverage ratio remind traders this is a high-risk biotech play, not a stable cash machine.
  • Technical traders are focused on the $0.60–$0.70 daily range as a key battleground for the next directional move in RDHL.

Candlestick Chart

Live Update At 07:47:55 EDT: On Monday, August 31, 2026 Redhill Biopharma Ltd. stock [NASDAQ: RDHL] is trending up by 139.03%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Redhill Biopharma Ltd., trading under ticker RDHL, is the classic small-cap biotech that lives on volatility, not steady profits. The income data show revenue around $8.0M, but the pretax profit margin sits near -108.7%. In simple terms, RDHL spends far more than it brings in. That’s normal for early or development-stage biopharma, but it raises risk for anyone trading the stock.

The balance sheet paints the same picture. RDHL shows total assets of about $25.3M and total liabilities around $21.1M, leaving stockholders’ equity near $4.3M. Working capital, however, is deeply negative at roughly -$12.7M, meaning current liabilities outweigh current assets. Cash and equivalents stand near $4.0M, so RDHL has some runway, but not a huge safety cushion.

More Breaking News

Key ratios back up the risk profile. Return on assets is about -40.8%, return on capital near -69.6%, and leverage runs high with a 5.9 ratio. RDHL also trades at a rich price-to-sales multiple around 14.0, and book value per share is negative. For traders, that says speculation, not value. RDHL can trend hard, but the fundamentals demand tight risk management.

Why Traders Are Watching RDHL Price Swings

RDHL has become a short-term trading vehicle thanks to its sharp moves on both the daily and intraday charts. Over the past couple of weeks, Redhill Biopharma Ltd. has bounced between closes near $0.58 and $0.66. That might sound like small change, but in percentage terms those swings are meaningful. A move from roughly $0.58 to $0.66 is more than 10%, which gets momentum traders’ attention.

Zoom in to the 5-minute chart and the story gets wilder. RDHL opened around $1.15 in the early premarket, ripped as high as $2.16, then yanked back to the mid-$1.80s and finally settled in the $1.50s. That is the kind of whipsaw action that can make or break a trader’s day in minutes. Redhill Biopharma Ltd. shows exactly why traders love low-priced biotech names: liquidity plus emotion equals big intraday ranges.

Technically, RDHL’s recent daily closes above $0.60 suggest short-term buyers are still in the game. The stock has tested the $0.58–$0.60 area multiple times and bounced, making that zone a clear support level for chart-focused traders. On the upside, the $0.65–$0.70 band marks resistance, where RDHL has struggled to hold gains.

For active traders, this creates a defined battlefield. RDHL offers potential breakout setups if it can hold above $0.70 on volume, but also potential fade trades if it fails at that range again. Redhill Biopharma Ltd. sits in that sweet spot where technicals, not long-term fundamentals, tend to drive the day-to-day tape.

Conclusion

RDHL is not a “set it and forget it” name. Redhill Biopharma Ltd. is a speculative biotech with weak profitability, negative returns on capital, high leverage, and limited working capital. Those fundamentals explain why the stock trades under $1 on the daily chart, even while intraday spikes can briefly push it above $1.50 or $2. For long-term stability, RDHL does not check many boxes. For volatility, it checks almost all of them.

Traders who focus on price action see a tight range forming between roughly $0.60 and $0.70 on the daily timeframe. If RDHL cracks below support near $0.58, momentum to the downside can accelerate. If it powers through $0.70 and holds, a short squeeze or momentum run is on the table. Either way, Redhill Biopharma Ltd. demands a clear plan.

The key is discipline. As Tim Sykes likes to say, “I’m not here to be right, I’m here to trade well — that means cutting losses fast and never falling in love with a stock.” As millionaire penny stock trader and teacher Tim Sykes, says, “The goal is not to win every trade but to protect your capital and keep moving forward.”. RDHL is a perfect example of why that mindset matters. Redhill Biopharma Ltd. may offer sharp moves and big percentage swings, but traders should treat it like a trading vehicle, not a comfortable long-term home. This analysis is for educational and research purposes only, and every trader must do their own homework before acting.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”